Our Company
A CONCEPT BORNE OUT OF NEED
After holding the hands of hundreds of children suffering from congenital heart disease, the founder of our technology felt there had to be a better way to provide care to children without having to rely on the highly restrictive MRI. Moreover, she still wanted to provide doctors with complete and full information that they need to monitor the heart state and make a confident diagnosis. It was this immediate need for change and compassion that eventually led to the idea of the VMS and the creation of Ventripoint.
ALWAYS TRUE TO OUR STORY
Ventripoint Diagnostics Ltd. (TSXV:VPT, OTCQB:VPTDF) is dedicated to improving diagnostic imaging by developing tools that offer higher performance, lower cost, faster turnaround times, and greater patient comfort.
Our flagship product, VMS+, enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. VMS+ is compatible with all standard echocardiology machines, bringing diagnosis and monitoring closer to the patient and providing clinicians with more timely results to support clinical decisions.
MANAGEMENT & BOARD OF DIRECTORS
Hugh MacNaught
CEO, Director
Mr. MacNaught is a Fortune 100 trained executive with thirty years experience in the innovation, development, financing, and commercialisation of medical and life science technologies. He has worked in roles ranging from product development and manufacturing to finance, business development and executive management. His background includes extensive experience in clinical diagnostics, therapeutics and diagnostic imaging. His familiarity with research translation and technology development within early stage companies includes several years as a venture capitalist and founding, leading and financing technology ventures.
During the past decade Hugh has provided guidance to university spin-outs, corporate venturing initiatives and served as a business mentor at several Canadian universities. He has served as a director for corporations and not-for-profit agencies, including serving as the Audit Chair for Genome Prairie. He sat on the Technology Commercialization Committee for the Alberta Heritage Foundation for Medical Research, and is currently a member of the Core Evaluation Team for the GAPP Program at Genome Canada.
Matt Dobson
Marketing Director
Matt brings 25 years of experience in technology bringing numerous new concepts to market. His has held roles in marketing, commercial, operations and finance in start-ups through to top-tier companies within Medical Devices, Consumer Electronic, Pharmaceutical, FMCG and Retail sectors.
Recent engagements include Gemina Labs where Matt was responsible for Product Strategy where he identified and championed “ease-of-use” as a strategic differentiator within the point of care test market.
Matt brings a wealth of marketing skills which have helped companies to really understand their customers, what issues they have and how to solve them through innovation. He is passionate about listening to the customer and improving the patient journey.
At VentriPoint, Matt is responsible for strategic marketing, helping to understand the market and competitor positioning. He is committed to working collaboratively with all members of the VentriPoint team to achieve the company’s strategic goals.
Matt has an MBA from the Judge Business School, University of Cambridge, UK and a BEng (Hons) in Mechanical Engineering from the University of Bath, UK.
Dr. George Adams
Chairman, Member of Nominating & Corporate Governance & Audit Committees
Dr. Adams is a scientist, a serial entrepreneur and a financier. His previous position was CEO of Amorfix Life Sciences (TSX:AMF) from 2005-2010. He was Chairman of Sernova Corp (TSXV:SVA) and President and CEO of the UT Innovations Foundation from 1999 until 2004. Prior to this, he held research and executive positions with Boston Scientific Inc, Pfizer Inc, Corvita Canada Inc., University of Ottawa and Canadian Red Cross, Blood Transfusion Service. He has been instrumental in founding over 30 companies who have raised $100 million and has been a Director of 10 venture capital funds and 10 start-up companies. .Dr. Adams was awarded a World Economic Foundation Technology Pioneer for 2007 and TBI Company of the year in 2009. Dr Adams has 124 scientific publications and is a reviewer for major scientific journals, federal granting agencies and Centres of Excellence.
Karl Pringle
Business Advisor
Dynamic and visionary B2B software and medical technology commercial leader with over 25 years of experience establishing and scaling high functioning commercial teams.
Fiona Fitzgerald
Director
Ms. Fitzgerald is the current National Zone Leader for Cytiva Life Science and accounts for all the commercial products in Canada. She has over two decades of experience working with GE in Canada and made the transition to Cytiva in March 2020. Ms. Fitzgerald has sat on multiple Government of Canada Federal Committees including NSERC’s CREATE program, which she later chaired, and several NSERC Centre of Excellence Evaluation committees. She currently holds three board memberships in CIMTEC, MDCC, and is on the Advisory Board for the Centre of Bioengineering and Biotechnology in Waterloo University. Ms. Firzgerald seeks to further develop the Life Sciences industry in Canada and will be focusing her efforts in the growth and development of Ventripoint.
Randy AuCoin
Director
Randy AuCoin is currently the President and CEO of Exact Imaging, the world leader in high-frequency ultrasound for early detection of prostate cancer. Mr. AuCoin has raised over $50 million of venture capital and has had senior roles in Quinton Electrophysiology Corporation, DICOMIT, VisualSonics Inc., and Imagistx Inc. He has extensive experience in fund raising, sales and marketing, operations, and finance. Mr. AuCoin aims to guide Ventripoint towards becoming the standard-of-care for cardiac ultrasound diagnostics.
Nicolas Coutin, PHD
Clinical Affairs
Nic was part of the partnering team at AbCellera, where he supported a number of initiatives. Nic was also head of UBC Skunkworx, where he was responsible for supporting four spin-outs to get seed-funded over a six month sprint. Prior to that, Nic led the Venture and core programming team at Creative Destruction Lab, where, with his team, he worked to identify, evaluate and develop relationships with expert mentors and ventures as well as supporting programming to accelerate the growth of alumni companies.